Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Depreciation & Amortization (CF) (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $989000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 18.8% year-over-year to $989000.0; the TTM value through Sep 2025 reached $4.2 million, down 25.47%, while the annual FY2024 figure was $5.1 million, 66.1% down from the prior year.
  • Depreciation & Amortization (CF) reached $989000.0 in Q3 2025 per SGMO's latest filing, roughly flat from $993000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $5.5 million in Q3 2023 and bottomed at $989000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $2.4 million, with a median of $2.2 million recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 87.87% in 2021, then crashed 77.83% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.7 million in 2021, then rose by 22.68% to $3.3 million in 2022, then tumbled by 45.35% to $1.8 million in 2023, then plummeted by 32.07% to $1.2 million in 2024, then decreased by 20.31% to $989000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $989000.0 in Q3 2025, $993000.0 in Q2 2025, and $1.0 million in Q1 2025.